Bethany J. Cavanagh
Known title: SVP, Finance and TreasurerCIK: 0002033155
Associated companies
Transaction History
| BEAM | ▼ Sell | Open Market | 187 | $5K | 10/1/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 3,242 | $80K | 4/1/2026 | View on chart |
| BEAM | ▲ Buy | Grant | 20,000 | $0 | 3/31/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 6,198 | $217K | 1/22/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 3,034 | $91K | 1/20/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 467 | $11K | 10/1/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 3,015 | $55K | 4/1/2025 | View on chart |
| BEAM | ▲ Buy | Grant | 10,000 | $0 | 3/31/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 6,287 | $220K | 2/18/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,117 | $28K | 1/2/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 289 | $7K | 10/1/2024 | View on chart |
| BEAM | ▲ Buy | Grant | 2,500 | $0 | 9/30/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Beam Therapeutics to present BEAM-301 data at ESGCT congress
Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.
Beam Therapeutics to present BEAM-301 data at ESGCT congress. Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.